突变造血祖细胞的动力学与多发性骨髓瘤的临床结局无关。

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.

作者信息

Guerrero Camila, Larrayoz Maria-Jose, Erdozain Irache, Puig Noemi, Cedena Maria-Teresa, Maia Catarina, Mañu Amagoia, Gordillo Natalia, Churruca Oihane, Alignani Diego, Sarvide Sarai, Vazquez Iria, Perez Cristina, Oriol Albert, Rosinol Laura, Ríos-Tamayo Rafael, Gonzalez-Perez Marta-Sonia, Gonzalez-Rodriguez Ana-Pilar, de Arriba Felipe, Moraleda Jose M, Martin Jesus, Palomera Luis, Cabañas Valentin, Calasanz Maria-Jose, Martinez-Lopez Joaquin, Mateos Maria-Victoria, Bladé Joan, Lahuerta Juan-Jose, San-Miguel Jesus F, Paiva Bruno

机构信息

Cancer Center Clinica Universidad de Navarra (CCUN), Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369, CB16/12/00489, Pamplona, Spain.

Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain.

出版信息

Blood Cancer Discov. 2025 May 5;6(3):203-216. doi: 10.1158/2643-3230.BCD-24-0274.

DOI:10.1158/2643-3230.BCD-24-0274

PMID:40232156

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12050965/

Abstract

SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.

摘要

多发性骨髓瘤患者发生的第二原发性恶性肿瘤（SPM）对生存有有害影响。CH患者可能有发生SPM的风险，通过个体化治疗有可能避免。然而，我们的结果表明，在诊断时筛查CH的效用有限。

相似文献

Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.突变造血祖细胞的动力学与多发性骨髓瘤的临床结局无关。

Blood Cancer Discov. 2025 May 5;6(3):203-216. doi: 10.1158/2643-3230.BCD-24-0274.

Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma.多发性骨髓瘤患者造血细胞中的嵌合染色体改变与临床结局。

Leukemia. 2024 Nov;38(11):2456-2465. doi: 10.1038/s41375-024-02396-3. Epub 2024 Sep 2.

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.接受大剂量化疗和自体造血干细胞移植的高危和标危多发性骨髓瘤患者的治疗结果

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):687-93. doi: 10.1016/j.clml.2015.07.641. Epub 2015 Aug 5.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.接受自体干细胞移植的多发性骨髓瘤患者中的克隆性造血

Leukemia. 2018 Sep;32(9):2020-2024. doi: 10.1038/s41375-018-0208-8. Epub 2018 Jul 19.

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.新型药物时代携带t(14;16)的多发性骨髓瘤患者的临床特征与生存情况

Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.新诊断多发性骨髓瘤中循环肿瘤细胞≥2%的临床结局：一项多中心研究的见解

Ann Med. 2025 Dec;57(1):2496796. doi: 10.1080/07853890.2025.2496796. Epub 2025 Apr 30.

Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.新标准定义的循环浆细胞百分比在多发性骨髓瘤和原发性浆细胞白血病中的预后意义

Acta Haematol. 2025;148(1):48-57. doi: 10.1159/000538658. Epub 2024 Apr 16.

The cellular architecture of multiple myeloma.多发性骨髓瘤的细胞结构

Cell Cycle. 2012 Oct 15;11(20):3715-7. doi: 10.4161/cc.22178. Epub 2012 Sep 14.

Hematopoietic reconstitution after autologous hematopoietic stem cell transplantation: do CD45 (+) CD34 (+) CD38 (-) progenitors really matter in real life?自体造血干细胞移植后的造血重建：CD45(+)CD34(+)CD38(-)祖细胞在实际情况中真的重要吗？

Transfus Apher Sci. 2018 Jun;57(3):406-408. doi: 10.1016/j.transci.2018.04.021. Epub 2018 Apr 24.

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.移植前重链/轻链比例标准化在多发性骨髓瘤中具有独立的预后意义：一项BMT CTN 0102相关研究。

Br J Haematol. 2017 Sep;178(5):816-819. doi: 10.1111/bjh.14170. Epub 2016 Jun 13.

本文引用的文献

Genomic Classification and Individualized Prognosis in Multiple Myeloma.多发性骨髓瘤的基因组分类和个体化预后。

J Clin Oncol. 2024 Apr 10;42(11):1229-1240. doi: 10.1200/JCO.23.01277. Epub 2024 Jan 9.

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.多发性骨髓瘤患者不可持续的可测量残留疾病阴性的预测因素。

Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.适合移植的多发性骨髓瘤患者中不可持续的可测量残留疾病阴性的预测因素。

Blood. 2024 Feb 15;143(7):597-603. doi: 10.1182/blood.2023022083.

Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者的临床结局和克隆性造血演变。

Cancer Res Commun. 2023 Dec 18;3(12):2560-2571. doi: 10.1158/2767-9764.CRC-23-0093.

Causes and consequences of clonal hematopoiesis.克隆性造血的原因和后果。

Blood. 2023 Dec 28;142(26):2235-2246. doi: 10.1182/blood.2023022222.

Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.在发展为继发性骨髓增生异常综合征的患者中，多发性骨髓瘤诊断时存在小的髓系亚克隆。

Haematologica. 2024 Apr 1;109(4):1289-1292. doi: 10.3324/haematol.2023.284050.

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.大 T 细胞克隆表达免疫检查点在多发性骨髓瘤演变过程中增加，并预测治疗耐药性。

Nat Commun. 2023 Sep 20;14(1):5825. doi: 10.1038/s41467-023-41562-6.

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.多发性骨髓瘤患者发生的第二原发性恶性肿瘤的结局

Cancers (Basel). 2023 Sep 1;15(17):4359. doi: 10.3390/cancers15174359.

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.来那度胺维持治疗新诊断的适合和不适合移植的骨髓瘤患者；对骨髓瘤XI试验中4358例患者的第二原发性恶性肿瘤进行分析。

EClinicalMedicine. 2023 Jul 27;62:102099. doi: 10.1016/j.eclinm.2023.102099. eCollection 2023 Aug.

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.来那度胺和地塞米松维持治疗联合或不联合伊沙佐米，根据骨髓瘤患者的残留疾病状态进行调整。

Blood. 2023 Nov 2;142(18):1518-1528. doi: 10.1182/blood.2022019531.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。